KI-Beratung Beta
Vor Ort
Merkzettel Warenkorb

Gutscheinbedingungen

**Gültig bis 05.10.2026 ab einem Mindestbestellwert von 30€ auf Spielzeug, Schreibwaren, Filme, Geschenke & Trends, Musik, tolino eReader & Zubehör, Hörbücher und Hörbuch-Downloads, nicht preisgebundene Bücher und Kalender online auf thalia.at und in der Thalia App. Einzelne Artikel können ausgeschlossen sein. Aufgrund der Buchpreisbindung sind deutschsprachige Bücher und eBooks ausgenommen. Zusätzlich ausgenommen sind Abos & Flatrates, Games, Geschenkkarten/-boxen, Shelfies, Software, Zeitschriften sowie einzelne Artikel von tonies®. Pro Einkauf einmal einlösbar. Nur gültig mit im Onlineshop hinterlegter Bonuscard. Click & Collect nur bei Onlinevorabzahlung möglich. Keine Barauszahlung. Nicht kombinierbar mit anderen Aktionen und Gutscheinen. Gutschein wird auf max. 500€ Bestellwert angerechnet. Nicht gültig für Versandkosten und Services. Preisgebundene Artikel sind vom Mindestbestellwert ausgeschlossen.
Produktbild: Biosimilars for Cancer Treatment
- 10%

Biosimilars for Cancer Treatment A Promising Approach

10% sparen

196,99 € UVP 219,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

03.07.2025

Abbildungen

XVI, 309 p. 25 illus., 24 illus. in color.

Herausgeber

Shvetank Bhatt + weitere

Verlag

Springer Singapore

Seitenzahl

309

Maße (L/B/H)

23,5/15,5/1,8 cm

Gewicht

499 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-981-9730-03-2

Beschreibung

Portrait


Dr. Shvetank Bhatt is currently working as an associate professor in the school of health sciences and technology, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, India. He has done M.Pharm in pharmacology from Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka, India and Ph.D. in neuropharmacology from Birla Institute of Technology and Science (BITS) Pilani, Pilani Campus, Rajasthan, India. His areas of specialization are CNS disorders, pain, inflammation and immuno oncology. He has published numerous papers. He is a life member of the Association of Pharmaceutical Teachers of India (APTI) and the Indian Pharmacological Society (IPS).


 


Dr. Harish Dureja is head of the department of pharmaceutical sciences, Maharshi Dayanand University, Rohtak, Haryana, India, and Director of the Centre for IPR Studies and Professional Consultancy Cell at M. D. University, Rohtak, India. He earned his master’s in pharmacy from Punjabi University,Patiala, India, and Ph.D. in pharmaceutical sciences from Maharshi Dayanand University, Rohtak, India. He has published numerous articles in journals of repute. Dr. Dureja is also actively engaged in committees of various central and state universities, namely the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Pharmacy Council of India (PCI), All India Council of Technical Education (AICTE), National Testing Agency (NTA) and National Assessment and Accreditation Council (NAAC), etc.


 


Dr. Samir Gunvantbhai Patel works as dean, faculty of pharmacy, professor, pharmaceutical chemistry and analysis, at Ramanbhai Patel College of Pharmacy (RPCP), Gujarat, India. He has more than 18 years of academic experience. His major research areas are design, synthesis and biological evaluation of cyclic peptides and synthetic derivatives for treating breast cancer, colon cancer and cancer metastasis. He has published several research articles and a few book chapters.


 


Dr. Archita Samir Patel is an assistant professor, pharmaceutical chemistry and analysis, Ramanbhai Patel College of Pharmacy (RPCP), Gujarat, India. She has more than 18 years of academic experience. Her major research areas are the analysis of small molecules, development and validation of stability indicating analytical methods for small molecules and herbal actives, impurity profiling of synthetic drug substances and developing analytical methods using a chemometrics approach. She has published several research articles and a few book chapters.


 


Dr. Kamal Dua is a senior lecturer in the discipline of pharmacy at the graduate school of health, University of Technology Sydney (UTS), Australia. He has research experience of over 13 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a node leader of drug delivery research in the centre for inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua's research in two complementary areas; drug delivery and immunology are evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published numerous research articles in journals of repute and authored and co-authored a few books. He is also an active member of many national and international professional societies.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

03.07.2025

Abbildungen

XVI, 309 p. 25 illus., 24 illus. in color.

Herausgeber

Verlag

Springer Singapore

Seitenzahl

309

Maße (L/B/H)

23,5/15,5/1,8 cm

Gewicht

499 g

Auflage

1. Auflage

Sprache

Englisch

ISBN

978-981-9730-03-2

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Biosimilars for Cancer Treatment

  • 1. An Overview of Biosimilars.- 2. Immunobiology of Cancer.- 3. Mechanism of Biosimilars for the treatment of Cancer.- 4. Biosimilars in Colorectal Cancer.- 5. Biosimilars in Cervical Caner.- 6. Biosimilars in Prostate Cancer.- 7. Biosimilars in Gastric Cancer.- 8. Biosimilars in Lung Cancer.- 9. A Recent Overview of The Growing Applications of Biosimilars in Pancreatic Cancer Management- Current Picture and Future Perspectives.- 10. Biosimilars in Breast Cancer.- 11. Biosimilars in Hepatocellular Carcinoma.- 12. Biosimilars in Ovarian Cancer.- 13. Biosimilars in Blood Cancer.- 14. Biosimilars in Clinical Trials.- 15. Regulatory Considerations of Biosimilars in Cancer.- 16. Future Scope of Biosimilars for the Treatment of Various Cancers.